Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
2 recherche sur le mot-clé 'Acamprosate'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Brief Report: Acamprosate in Fragile X Syndrome / Craig ERICKSON in Journal of Autism and Developmental Disorders, 40-11 (November 2010)
[article]
Titre : Brief Report: Acamprosate in Fragile X Syndrome Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Jennifer E. MULLETT, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2010 Article en page(s) : p.1412-1416 Langues : Anglais (eng) Mots-clés : Acamprosate Fragile X syndrome mGluR5 Language Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism. En ligne : http://dx.doi.org/10.1007/s10803-010-0988-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=114
in Journal of Autism and Developmental Disorders > 40-11 (November 2010) . - p.1412-1416[article] Brief Report: Acamprosate in Fragile X Syndrome [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Jennifer E. MULLETT, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2010 . - p.1412-1416.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 40-11 (November 2010) . - p.1412-1416
Mots-clés : Acamprosate Fragile X syndrome mGluR5 Language Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism. En ligne : http://dx.doi.org/10.1007/s10803-010-0988-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=114 Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)
[article]
Titre : Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2014 Article en page(s) : p.981-987 Langues : Anglais (eng) Mots-clés : Acamprosate Autism spectrum disorder Glutamate Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ?25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987[article] Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Logan K. WINK, Auteur ; Maureen C. EARLY, Auteur ; Elizabeth STIEGELMEYER, Auteur ; Lauren MATHIEU-FRASIER, Auteur ; Vanessa PATRICK, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2014 . - p.981-987.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 44-4 (April 2014) . - p.981-987
Mots-clés : Acamprosate Autism spectrum disorder Glutamate Gamma-aminobutyric acid Index. décimale : PER Périodiques Résumé : An excitatory/inhibitory (E:I) imbalance marked by enhanced glutamate and deficient gamma-aminobutyric acid (GABA) neurotransmission may contribute to the pathophysiology of autism spectrum disorders (ASD). We report on the first single-blind placebo lead-in trial of acamprosate, a drug with putative mechanisms restoring E:I imbalance, in twelve youth with ASD. We conducted a 12-week single-blind, placebo lead-in study of acamprosate in youth age 5–17 years with autistic disorder. Six of nine subjects who received active drug treatment were deemed treatment responders (defined by a score at final visit of “very much improved” or “much improved” on the Clinical Global Impressions Improvement scale) and ?25 % improvement on the Aberrant Behavior Checklist Social Withdrawal subscale. Future larger-scale dose finding studies of acamprosate in ASD may be warranted given this preliminary indication of benefit. En ligne : http://dx.doi.org/10.1007/s10803-013-1943-3 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=228